BACKGROUND: Previous studies have shown that summary measures of comorbid conditions are associated with decreased overall survival in breast cancer patients. However, less is known about associations between specific comorbid conditions on the survival of breast cancer patients. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to identify primary breast cancers diagnosed from 1992 to 2000 among women aged 66 years or older. Inpatient, outpatient, and physician visits within the Medicare system were searched to determine the presence of 13 comorbid conditions present at the time of diagnosis. Overall survival was estimated using age-specific Kaplan-Meier curves, and mortality was estimated using Cox proportional hazards models adjusted for age, race and/or ethnicity, tumor stage, cancer prognostic markers, and treatment. All statistical tests were two-sided. RESULTS: The study population included 64,034 patients with breast cancer diagnosed at a median age of 75 years. None of the selected comorbid conditions were identified in 37,306 (58%) of the 64,034 patients in the study population. Each of the 13 comorbid conditions examined was associated with decreased overall survival and increased mortality (from prior myocardial infarction, adjusted hazard ratio [HR] of death = 1.11, 95% CI = 1.03 to 1.19, P = .006; to liver disease, adjusted HR of death = 2.32, 95% CI = 1.97 to 2.73, P < .001). When patients of age 66-74 years were stratified by stage and individual comorbidity status, patients with each comorbid condition and a stage I tumor had similar or poorer overall survival compared with patients who had no comorbid conditions and stage II tumors. CONCLUSIONS: In a US population of older breast cancer patients, 13 individual comorbid conditions were associated with decreased overall survival and increased mortality.
BACKGROUND: Previous studies have shown that summary measures of comorbid conditions are associated with decreased overall survival in breast cancerpatients. However, less is known about associations between specific comorbid conditions on the survival of breast cancerpatients. METHODS: The Surveillance, Epidemiology, and End Results-Medicare database was used to identify primary breast cancers diagnosed from 1992 to 2000 among women aged 66 years or older. Inpatient, outpatient, and physician visits within the Medicare system were searched to determine the presence of 13 comorbid conditions present at the time of diagnosis. Overall survival was estimated using age-specific Kaplan-Meier curves, and mortality was estimated using Cox proportional hazards models adjusted for age, race and/or ethnicity, tumor stage, cancer prognostic markers, and treatment. All statistical tests were two-sided. RESULTS: The study population included 64,034 patients with breast cancer diagnosed at a median age of 75 years. None of the selected comorbid conditions were identified in 37,306 (58%) of the 64,034 patients in the study population. Each of the 13 comorbid conditions examined was associated with decreased overall survival and increased mortality (from prior myocardial infarction, adjusted hazard ratio [HR] of death = 1.11, 95% CI = 1.03 to 1.19, P = .006; to liver disease, adjusted HR of death = 2.32, 95% CI = 1.97 to 2.73, P < .001). When patients of age 66-74 years were stratified by stage and individual comorbidity status, patients with each comorbid condition and a stage I tumor had similar or poorer overall survival compared with patients who had no comorbid conditions and stage II tumors. CONCLUSIONS: In a US population of older breast cancerpatients, 13 individual comorbid conditions were associated with decreased overall survival and increased mortality.
Authors: W J Louwman; M L G Janssen-Heijnen; S Houterman; A C Voogd; M J C van der Sangen; G A P Nieuwenhuijzen; J W W Coebergh Journal: Eur J Cancer Date: 2005-03 Impact factor: 9.162
Authors: Young Chandler; Jinani C Jayasekera; Clyde B Schechter; Claudine Isaacs; Christopher J Cadham; Jeanne S Mandelblatt Journal: J Natl Cancer Inst Date: 2020-06-01 Impact factor: 13.506
Authors: Stein J Janssen; Andrea S van der Heijden; Maarten van Dijke; John E Ready; Kevin A Raskin; Marco L Ferrone; Francis J Hornicek; Joseph H Schwab Journal: Clin Orthop Relat Res Date: 2015-07-09 Impact factor: 4.176
Authors: Rifaquat Rahman; Paul J Catalano; David A Reardon; Andrew D Norden; Patrick Y Wen; Eudocia Q Lee; Lakshmi Nayak; Rameen Beroukhim; Ian F Dunn; Alexandra J Golby; Mark D Johnson; E Antonio Chiocca; Elizabeth B Claus; Brian M Alexander; Nils D Arvold Journal: J Neurooncol Date: 2015-06-02 Impact factor: 4.130
Authors: Marloes G M Derks; Cornelis J H van de Velde; Daniele Giardiello; Caroline Seynaeve; Hein Putter; Johan W R Nortier; Luc Y Dirix; Esther Bastiaannet; Johanneke E A Portielje; Gerrit-Jan Liefers Journal: Oncologist Date: 2019-01-03
Authors: Trevor A Jolly; Allison M Deal; Kirsten A Nyrop; Grant R Williams; Mackenzi Pergolotti; William A Wood; Shani M Alston; Brittaney-Belle E Gordon; Samara A Dixon; Susan G Moore; W Chris Taylor; Michael Messino; Hyman B Muss Journal: Oncologist Date: 2015-03-12
Authors: Jennifer H Jordan; Soe Soe Thwin; Timothy L Lash; Diana S M Buist; Terry S Field; Reina Haque; Pamala A Pawloski; Hans V Petersen; Marianne N Prout; Virginia P Quinn; Marianne Ulcickas Yood; Rebecca A Silliman; Ann M Geiger Journal: Breast Cancer Res Treat Date: 2014-06-18 Impact factor: 4.872
Authors: Catherine Marinac; Ruth E Patterson; Adriana Villasenor; Shirley W Flatt; John P Pierce Journal: J Cancer Surviv Date: 2014-02-26 Impact factor: 4.442